Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in melanoma

S S Agarwala1, J M Kirkwood

  • 1Division of Medical Oncology, University of Pittsburgh Cancer Institute, PA 15213-2582, USA.

Current Opinion in Oncology
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year survival with tebentafusp in metastatic uveal melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis.

Immuno-oncology technology·2025
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Schilling et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Targeting the MAPK pathway in advanced BRAF wild-type melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey.

The British journal of dermatology·2018
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Interferon-alpha shows promise for high-risk melanoma patients, improving survival in adjuvant therapy. Combination therapies are being investigated to enhance treatment effectiveness for metastatic melanoma.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Interferons (IFNs) are proteins investigated for cancer therapy.
  • Interferon-alpha (IFN-alpha) is extensively studied for melanoma treatment.
  • Current research explores IFN-alpha combinations to improve response rates.

Purpose of the Study:

  • To evaluate the efficacy of Interferon-alpha in melanoma treatment.
  • To assess the role of IFN-alpha in both metastatic and adjuvant settings.
  • To explore combination therapies involving IFNs for melanoma.

Main Methods:

  • Review of clinical trials and treatment outcomes for Interferon-alpha in melanoma.
  • Analysis of response rates in metastatic melanoma treated with IFN-alpha.
  • Evaluation of survival data from adjuvant therapy trials, such as E1684.

Related Experiment Videos

Main Results:

  • IFN-alpha yields responses in approximately 16% of metastatic melanomas.
  • Positive results from trial E1684 demonstrate improved survival in high-risk adjuvant melanoma patients treated with IFN-alpha.
  • IFN-gamma shows limited efficacy in metastatic and high-risk melanoma but is effective for locoregional disease.

Conclusions:

  • Maximally tolerated doses of IFN-alpha are recommended.
  • IFN-alpha offers a brighter outlook in the adjuvant setting for high-risk melanoma.
  • Further research is needed on sequencing, administration, and toxicity reduction for IFNs in melanoma treatment.